期刊文献+

胃癌SGC7901表柔比星耐药细胞亚系的建立与耐药机制研究 被引量:1

The Mechanisms of Drug Resistance in Newly Established Epirubicin-Resistant Gastric Cancer Cell Line
原文传递
导出
摘要 目的:建立人胃癌SGC7901表柔比星耐药细胞系,探讨其对表柔比星的耐药机制。方法:采用逐步增加表柔比星浓度,间歇作用体外诱导法,建立人胃癌SGC7901表柔比星耐药细胞亚系SGC7901/EPI。用MTT法测定药物敏感性;流式细胞仪检测其药物排除能力和凋亡抵抗能力等生物学指标的改变,western blot检测相关蛋白的表达。结果:经过12个月建成人胃癌SGC7901表柔比星耐药细胞系SGC7901/EPI,其对表柔比星明显耐药,且对其他多种抗癌药具有不同程度的交叉耐药性,阿霉素蓄积潴留实验显示SGC7901/EPI的阿霉素含量明显低于亲本细胞,Western blot显示MRP1的表达上调;SGC7901/EPI凋亡抵抗能力明显上升,Bcl-2表达比亲本细胞增高,而Bax的表达下调。结论:SGC7901/EPI细胞具有多药耐药表型,其可能通过MRP1的上调增加药物排出和上调Bcl-2/Bax的比值促进凋亡抵抗等机制产生耐药。该胃癌多药耐药细胞亚系为进一步研究胃癌耐药机制及逆转方法奠定基础。 Objective: To establish the drug resistant cell model of gastric cancer and investigate the potential mechanisms of epirubicin drug resistance.Methods: Epirubicin-resistant cell line(SGC7901/EPI) was established by increasing dose of epirubicin.Drug sensitivity of the cell line was measured by in vitro MTT assay.Cell based assays for drug transportation and apoptosis were carried out.The expression levels of MRP1,Bcl-2,Bax were detected using western blot.Results: Significant difference was found in drug resistance between parent gastric cancer cell line SGC7901 and drug resistant subline 7901/EPI.Compared with SGC7901 cells,7901/EPI showed not only increased drug resistance,but also decreased drug sensitivity to other drugs.Increased drug transport was confirmed by the elevated expressions of MRP in 7901/EPI.Apoptosis rate of the SGC7901/EPI cell line was remarkably reduced due to increased expression of Bcl-2 and decreased Bax.Conclusion: Epirubicin resistant gastric cancer cell subline SGC7901/EPI was successfully established.The mechanisms of epirubicin may include elevated expression of MRP1 and increased Bcl-2/Bax ratio.
出处 《现代生物医学进展》 CAS 2012年第14期2658-2662,共5页 Progress in Modern Biomedicine
基金 国家自然科学基金项目"MAD2及其选择性剪切体MAD2β在人胃癌干细胞中的表达及其对胃癌干细胞耐药调控机制的研究(30973422)
关键词 胃癌 多药耐药 表柔比星 Gastric cancer; Multidrug resistance; Epirubicin
  • 相关文献

参考文献17

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics[J].CA Can- cer J Clin, 2011, 61(2): 69-90.
  • 2Price TJ, Shapiro JD, Segelov E, et al. Management of advanced gastr- ic cancer[J].Expert Rev Gastroenterol Hepatol, 2012, 6(2): 199-209.
  • 3Zhang D, Fan D. Multidmg resistance in gastric cancer: recent resea- rch advances and ongoing therapeutic challenges[J]. Expert Rev Anti- cancer Ther, 2007, 7(10): 1369-1378.
  • 4Szakacs G, Paterson JK, Ludwig JA, et al. Targeting multidrug resista- nce in cancer[J]. Nat Rev Drug Discov, 2006, 5(3): 219-234.
  • 5Yuan G, Regel I, Lian F, et al. WNT6 is a novel target gene of caveoli- n-1 promoting chemoresistance to epirubicin in human gastric cancer cells[J]. Oncogene, 2012. [Epub ahead of print].
  • 6Rivera F, Vega-Villegas ME, Lopez-Brea MF. Chemotherapy of adva- nced gastric cancer[J].Cancer Treat Rev, 2007, 33(4): 315-324.
  • 7Li X H, Li C, Xiao ZQ. Proteomics for identifying mechanisms and biomarkers of drug resistance in cancer[J]. J Proteomics, 2011, 74(12): 2642-2649.
  • 8Chiodi I, Belgiovine C, Dona F, et al. Drug Treatment of Cancer Cell Lines: A Way to Select for Cancer Stem Cells?[J].Cancers, 2011, 3(1): 1111-1128.
  • 9Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer[J].Oncogene, 2010, 29(34): 4741 -4751.
  • 10Plosker GL, Faulds D. Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chem- otherapy[J]. Drugs, 1993, 45(5): 788-856.

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部